THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
The information in this Current Report (including Exhibit99.1) is being furnished and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit99.1) shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Between January8-11, 2018, members of the Theravance Biopharma,Inc. management team will be conducting one-on-one meetings with analysts and investors in San Francisco, CA. A copy of the slide presentation is being furnished to Regulation FD as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
99.1 Investor presentation dated January2018
Theravance Biopharma, Inc. ExhibitEX-99.1 2 a18-2406_1ex99d1.htm EX-99.1 Exhibit 99.1 Investor Presentation January 2018 Theravance Biopharma,…To view the full exhibit click
About THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH)
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
An ad to help with our costs